Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 4
2009 5
2010 9
2011 11
2012 25
2013 58
2014 94
2015 121
2016 168
2017 239
2018 238
2019 271
2020 376
2021 438
2022 473
2023 460
2024 214

Text availability

Article attribute

Article type

Publication date

Search Results

2,799 results

Results by year

Filters applied: . Clear all
Page 1
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.
Goldenberg RM, Berard LD, Cheng AYY, Gilbert JD, Verma S, Woo VC, Yale JF. Goldenberg RM, et al. Clin Ther. 2016 Dec;38(12):2654-2664.e1. doi: 10.1016/j.clinthera.2016.11.002. Clin Ther. 2016. PMID: 28003053 Review.
Practical recommendations for diagnosis and prevention were established by the panel. FINDINGS: DKA is rarely associated with SGLT2 inhibitor therapy. Patients with SGLT2 inhibitor-associated DKA may be euglycemic (plasma glucose level <14 mmol/L). …
Practical recommendations for diagnosis and prevention were established by the panel. FINDINGS: DKA is rarely associated with SGLT2 …
SGLT2 inhibitor activates the STING/IRF3/IFN-beta pathway and induces immune infiltration in osteosarcoma.
Wu W, Zhang Z, Jing D, Huang X, Ren D, Shao Z, Zhang Z. Wu W, et al. Cell Death Dis. 2022 Jun 3;13(6):523. doi: 10.1038/s41419-022-04980-w. Cell Death Dis. 2022. PMID: 35662245 Free PMC article.
In addition, the combined treatment with SGLT2 inhibitor and STING agonist 2'3'-cGAMP exerted synergistic antitumor effects in osteosarcoma. ...This result demonstrated that SGLT2 is a novel therapeutic target of osteosarcoma, and that the SGLT2 inhibitor …
In addition, the combined treatment with SGLT2 inhibitor and STING agonist 2'3'-cGAMP exerted synergistic antitumor effects in …
SGLT2 inhibitor plus DPP-4 inhibitor as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
Li D, Shi W, Wang T, Tang H. Li D, et al. Diabetes Obes Metab. 2018 Aug;20(8):1972-1976. doi: 10.1111/dom.13294. Epub 2018 Apr 14. Diabetes Obes Metab. 2018. PMID: 29573110 Free article.
Adding a DPP-4 inhibitor to an SGLT2 inhibitor could reduce HbA1c by -0.31%, FPG by -8.94 mg/dL, TC by -1.48% and triglycerides by -3.25%. Interestingly, low doses of an SGLT2 inhibitor in the combination has similar or even better efficacy in some asp …
Adding a DPP-4 inhibitor to an SGLT2 inhibitor could reduce HbA1c by -0.31%, FPG by -8.94 mg/dL, TC by -1.48% and triglyceride …
Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.
Blau JE, Tella SH, Taylor SI, Rother KI. Blau JE, et al. Diabetes Metab Res Rev. 2017 Nov;33(8):10.1002/dmrr.2924. doi: 10.1002/dmrr.2924. Epub 2017 Sep 29. Diabetes Metab Res Rev. 2017. PMID: 28736981 Free PMC article.
METHODS: We searched the FDA Adverse Event Reporting System (FAERS) for reports of acidosis in patients treated with canagliflozin, dapagliflozin, or empagliflozin (from the date of each drug's FDA approval until May 15, 2015). We compared the number of SGLT2 inhibitor …
METHODS: We searched the FDA Adverse Event Reporting System (FAERS) for reports of acidosis in patients treated with canagliflozin, dapaglif …
EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors.
Fernández-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. Fernández-Fernandez B, et al. Clin Kidney J. 2023 Jun 16;16(8):1187-1198. doi: 10.1093/ckj/sfad082. eCollection 2023 Aug. Clin Kidney J. 2023. PMID: 37529652 Free PMC article.
The representation of diverse causes of CKD (>1600 participants with glomerular disease, >1400 with hypertensive kidney disease, >450 with tubulointerstitial disease and >600 with unknown cause) was higher than in prior SGLT2 inhibitor trials, although p …
The representation of diverse causes of CKD (>1600 participants with glomerular disease, >1400 with hypertensive kidney disease, >4 …
SGLT2 inhibitor therapy in patients with type-2 diabetes mellitus: is acute kidney injury a concern?
Baker ML, Perazella MA. Baker ML, et al. J Nephrol. 2020 Oct;33(5):985-994. doi: 10.1007/s40620-020-00712-5. Epub 2020 Feb 18. J Nephrol. 2020. PMID: 32067179 Review.
Sodium-glucose co-transporter-2 (SGLT2) inhibitor drugs are effective for treatment of type-2 diabetes mellitus. ...However, despite these beneficial cardiovascular and kidney effects, numerous reports of acute kidney injury, including need for dialysis and death, h …
Sodium-glucose co-transporter-2 (SGLT2) inhibitor drugs are effective for treatment of type-2 diabetes mellitus. ...However, d …
Dose-dependent relationship between SGLT2 inhibitor hold time and risk for postoperative anion gap acidosis: a single-centre retrospective analysis.
Steinhorn B, Wiener-Kronish J. Steinhorn B, et al. Br J Anaesth. 2023 Oct;131(4):682-686. doi: 10.1016/j.bja.2023.06.063. Epub 2023 Aug 2. Br J Anaesth. 2023. PMID: 37541949
CONCLUSIONS: These findings provide the first evidence that an anion gap acidosis, likely from ketoacids, develops in all patients who do not hold SGLT2 inhibitors before surgery rather than in an idiosyncratic few. If an SGLT2 inhibitor is unable to be stopped, pos …
CONCLUSIONS: These findings provide the first evidence that an anion gap acidosis, likely from ketoacids, develops in all patients who do no …
Gliflozin (SGLT2 inhibitor) induced vulvitis.
Mounsey SJ, Teo YX, Calonje JE, Lewis FM. Mounsey SJ, et al. Int J Dermatol. 2023 Jan;62(1):62-65. doi: 10.1111/ijd.16449. Epub 2022 Oct 17. Int J Dermatol. 2023. PMID: 36250299
Cutaneous features of patients experiencing vulval symptoms while on SGLT2 inhibitor therapy have not been clearly described in published literature. ...
Cutaneous features of patients experiencing vulval symptoms while on SGLT2 inhibitor therapy have not been clearly described i …
2,799 results